Brisdelle is licensed to treat hot flashes caused by menopause. It comes in the form of a capsule that is taken once daily at bedtime. The medication is a type of selective serotonin reuptake inhibitor and is the first non-hormonal drug approved by the FDA for treating hot flashes associated with menopause. Side effects can include headaches, nausea, and fatigue.
Brisdelle™ (paroxetine mesylate capsules) is a prescription medication approved to treat hot flashes associated with menopause. It belongs to a class of medicines known as selective serotonin reuptake inhibitors (SSRIs). Brisdelle is the first non-hormonal medication approved by the U.S. Food and Drug Administration (FDA) for treating hot flashes due to menopause.
Brisdelle is made by Noven Therapeutics, LLC.
As mentioned, Brisdelle belongs to a class of medicines called selective serotonin reuptake inhibitors (SSRIs). SSRIs work to increase serotonin activity by increasing the amount of serotonin available in the small space between the cells in the body.
Serotonin has many functions in the body, including effects on mood and behavior. It is unknown how Brisdelle works to reduce hot flashes, but it is likely related to the drug's effects on serotonin. It is thought that changes in serotonin levels somehow contribute to the development of hot flashes during menopause.